CA2437940A1 - Methods of treating diabetes mellitus - Google Patents
Methods of treating diabetes mellitus Download PDFInfo
- Publication number
- CA2437940A1 CA2437940A1 CA002437940A CA2437940A CA2437940A1 CA 2437940 A1 CA2437940 A1 CA 2437940A1 CA 002437940 A CA002437940 A CA 002437940A CA 2437940 A CA2437940 A CA 2437940A CA 2437940 A1 CA2437940 A1 CA 2437940A1
- Authority
- CA
- Canada
- Prior art keywords
- insulin
- moiety
- human
- patient
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract 268
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract 81
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract 766
- 102000004877 Insulin Human genes 0.000 claims abstract 446
- 108090001061 Insulin Proteins 0.000 claims abstract 446
- 229940125396 insulin Drugs 0.000 claims abstract 377
- 239000003814 drug Substances 0.000 claims abstract 36
- 229940079593 drug Drugs 0.000 claims abstract 29
- 125000000217 alkyl group Chemical group 0.000 claims 57
- 230000037406 food intake Effects 0.000 claims 56
- 235000012054 meals Nutrition 0.000 claims 56
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 48
- 125000003827 glycol group Chemical group 0.000 claims 46
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 42
- 239000008103 glucose Substances 0.000 claims 42
- 230000009229 glucose formation Effects 0.000 claims 42
- 230000002440 hepatic effect Effects 0.000 claims 42
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 40
- 229920001515 polyalkylene glycol Polymers 0.000 claims 40
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims 34
- 125000005313 fatty acid group Chemical group 0.000 claims 28
- 230000002093 peripheral effect Effects 0.000 claims 28
- 239000002202 Polyethylene glycol Substances 0.000 claims 26
- 229920001223 polyethylene glycol Polymers 0.000 claims 26
- 239000000203 mixture Substances 0.000 claims 25
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 24
- 150000001408 amides Chemical group 0.000 claims 24
- 125000004432 carbon atom Chemical group C* 0.000 claims 24
- 125000005587 carbonate group Chemical group 0.000 claims 24
- 235000012000 cholesterol Nutrition 0.000 claims 24
- 150000002148 esters Chemical group 0.000 claims 24
- 125000001033 ether group Chemical group 0.000 claims 24
- 150000007970 thio esters Chemical group 0.000 claims 24
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 24
- 150000003558 thiocarbamic acid derivatives Chemical group 0.000 claims 23
- 210000004369 blood Anatomy 0.000 claims 21
- 239000008280 blood Substances 0.000 claims 21
- 210000003240 portal vein Anatomy 0.000 claims 21
- 125000003158 alcohol group Chemical group 0.000 claims 18
- 239000004472 Lysine Substances 0.000 claims 16
- 230000000291 postprandial effect Effects 0.000 claims 14
- 239000004026 insulin derivative Substances 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 230000037396 body weight Effects 0.000 claims 7
- 210000005259 peripheral blood Anatomy 0.000 claims 7
- 239000011886 peripheral blood Substances 0.000 claims 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000006850 spacer group Chemical group 0.000 claims 6
- 229910001573 adamantine Inorganic materials 0.000 claims 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- 230000014101 glucose homeostasis Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Methods of treating diabetes mellitus in a patient in need of such treatment include administering an effective amount of an insulin drug to the patient in order to treat diabetes mellitus in the patient. Methods according to the present invention may "activate" the liver, potentially restoring normal glucose homeostasis to individuals suffering from diabetes mellitus.
Claims (339)
1. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide derivative to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide derivative is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
orally administering an effective amount of an insulin polypeptide derivative to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide derivative is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
2. A method according to Claim 1, wherein the oral administration of the effective amount of the insulin polypeptide derivative provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 30 minutes of administration.
3. A method according to Claim 1, wherein the effective amount of the insulin polypeptide derivative is between about 0.05 and about 10 mg per kilogram body weight.
4. A method according to Claim 1, wherein the oral administration of the effective amount of the insulin polypeptide derivative provides a maximum insulin drug concentration in peripheral blood within about 60 minutes.
5. A method according to Claim 1, wherein the oral administration of the effective amount of the insulin polypeptide derivative stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
6. A method according to Claim 1, wherein the insulin polypeptide derivative clears the bloodstream of the patient within about 4 hours following administration.
7. A method according to Claim 1, wherein the administration of the effective amount of the insulin polypeptide derivative reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
8. A method according to Claim 7, wherein the reduction in hepatic glucose production occurs within about 90 minutes of administration.
9. A method according to Claim 1, wherein the insulin polypeptide derivative is orally administered such that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes after ingestion of the meal.
10. A method according to Claim 1, wherein the insulin polypeptide derivative is orally administered less than about one hour prior to ingestion of a meal by the patient.
11. A method according to Claim 1, wherein the insulin polypeptide derivative is orally administered substantially contemporaneously with the ingestion of a meal by the patient.
12. A method according to Claim 1, wherein the insulin polypeptide derivative is orally administered less than about one hour after ingestion of a meal by the patient.
13. A method according to Claim 1, wherein the insulin polypeptide in the insulin polypeptide derivative is insulin.
14. A method according to Claim 1, wherein the insulin polypeptide derivative is an insulin polypeptide-oligomer conjugate.
15. A method according to Claim 14, wherein the insulin polypeptide-oligomer conjugate is an amphiphilically balanced insulin polypeptide-oligomer conjugate.
16. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an amphiphilically-balanced insulin polypeptide-oligomer conjugate to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
orally administering an effective amount of an amphiphilically-balanced insulin polypeptide-oligomer conjugate to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
17. A method according to Claim 16, wherein the oral administration of the effective amount of the amphiphilically balanced insulin polypeptide-oligomer conjugate provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 30 minutes of administration.
18. A method according to Claim 16, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is between about 0.05 and about 10 mg per kilogram body weight.
19. A method according to Claim 16, wherein the oral administration of the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate provides a maximum insulin drug concentration in peripheral blood within about 60 minutes.
20. A method according to Claim 16, wherein the oral administration of the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
21 . A method according to Claim 16, wherein the amphiphilically-balanced insulin polypeptide-oligomer conjugate clears the bloodstream of the patient within about 4 hours following administration.
22. A method according to Claim 16, wherein the administration of the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
23. A method according to Claim 22, wherein the reduction in hepatic glucose production occurs within about 90 minutes of administration.
24. A method according to Claim 16, wherein the amphiphilically-balanced insulin polypeptide-oligomer conjugate is orally administered such that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes after ingestion of the meal.
25. A method according to Claim 16, wherein the amphiphilically-balanced insulin polypeptide-oligomer conjugate is orally administered less than about one hour prior to ingestion of a meal by the patient.
26. A method according to Claim 16, wherein the amphiphilically-balanced insulin polypeptide-oligomer conjugate is orally administered substantially contemporaneously with the ingestion of a meal by the patient.
27. A method according to Claim 16, wherein the amphiphilically-balanced insulin polypeptide-oligomer conjugate is orally administered less than about one hour after ingestion of a meal by the patient.
28. A method according to Claim 16, wherein the insulin polypeptide is insulin.
29. A method according to Claim 28, wherein the oligomer is coupled to the lysine at the B29 position of the insulin.
30. A method according to Claim 16, wherein the insulin polypeptide is an insulin analog selected from the group consisting of Gly A21 insulin, human; Gly A21 Gln B3 insulin, human; Ala A21 insulin, human; Ala A21 Gln B3 insulin, human; Gln B3 insulin, human; Gln B30 insulin, human; Gly A21 Glu B30 insulin, human; Gly A21 Gln B3 Glu B30 insulin, human; Gln B3 Glu B30 insulin, human; Asp B28 insulin, human; Lys B28 insulin, human; Leu B28 insulin, human;
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
31. A method according to Claim 16, wherein the amphiphilically-balanced insulin polypeptide oligomer conjugate is present as a substantially monodispersed mixture.
32. A method according to Claim 16, wherein the amphiphilically-balanced insulin polypeptide-oligomer conjugate is present as a monodispersed mixture.
33. A method according to Claim 16, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is present in a pharmaceutical composition.
34. A method according to Claim 16, wherein the amphiphilically-balanced insulin polypeptide-oligomer conjugate comprises a hydrophilic moiety and a lipophilic moiety.
35. A method according to Claim 34, wherein the hydrophilic moiety is a polyalkylene glycol moiety.
36. A method according to Claim 34, wherein the polyalkylene glycol moiety is a polyethylene glycol moiety.
37. A method according to Claim 34, wherein the polyalkylene glycol moiety has between 1 and 50 polyalkylene glycol subunits.
38. A method according to Claim 34, wherein the polyalkylene glycol moiety has between 3 and 50 polyalkylene glycol subunits.
39. A method according to Claim 34, wherein the polyalkylene glycol moiety has between 2 and 10 polyalkylene glycol subunits.
40. A method according to Claim 34, wherein the polyalkylene glycol moiety has between 4 and 10 polyalkylene glycol subunits.
41. A method according to Claim 34, wherein the polyalkylene glycol moiety has at least 2 polyalkylene glycol subunits.
42. A method according to Claim 34, wherein the lipophilic moiety is an alkyl or fatty acid moiety.
43. A method according to Claim 34, wherein the lipophilic moiety has between and 28 carbon atoms.
44. A method according to Claim 34, wherein the lipophilic moiety has between and 24 carbon atoms.
45. A method according to Claim 34, wherein the lipophilic moiety has between and 18 carbon atoms.
46. A method according to Claim 34, wherein the lipophilic moiety has between and 12 carbon atoms.
47. A method according to Claim 34, wherein the lipophilic moiety has between and 7 carbon atoms.
48. A method according to Claim 34, wherein the lipophilic moiety has between and 14 carbon atoms.
49. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula I:
Insulin Polypeptide~B~L j~G k~R~G'm~R'~G"n~T (I) wherein:
B is a bonding moiety;
L is a linker moiety;
G, G' and G" are individually selected spacer moieties;
R is a lipophilic moiety and R' is a polyalkylene glycol moiety, or R' is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety; and j, k, m and n are individually 0 or 1;
to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the conjugate of Formula I is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula I:
Insulin Polypeptide~B~L j~G k~R~G'm~R'~G"n~T (I) wherein:
B is a bonding moiety;
L is a linker moiety;
G, G' and G" are individually selected spacer moieties;
R is a lipophilic moiety and R' is a polyalkylene glycol moiety, or R' is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety; and j, k, m and n are individually 0 or 1;
to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the conjugate of Formula I is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
50. A method according to Claim 49, wherein the oral administration of the effective amount of the conjugate of Formula I provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 30 minutes of administration.
51. A method according to Claim 49, wherein the effective amount of the conjugate of Formula I is between about 0.05 and 10 mg per kilogram body weight.
52. A method according to Claim 49, wherein the oral administration of the effective amount of the conjugate of Formula I provides a maximum insulin drug concentration in peripheral blood within about 60 minutes after administration.
53. A method according to Claim 49, wherein the oral administration of the effective amount of the conjugate of Formula I stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
54. A method according to Claim 49, wherein the conjugate of Formula I clears the bloodstream of the patient within about 4 hours following administration.
55. A method according to Claim 49, wherein the administration of the effective amount of the conjugate of Formula I reduces hepatic glucose production in the patient by at Least about 25 percent when compared to hepatic glucose production in the patient without administration.
56. A method according to Claim 55, wherein the reduction in hepatic glucose production occurs within about 90 minutes after administration.
57. A method according to Claim 49, wherein the conjugate of Formula I is orally administered such that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes after ingestion of the meal.
58. A method according to Claim 49, wherein the conjugate of Formula I is orally administered less than about one hour prior to ingestion of a meal by the patient.
59. A method according to Claim 49, wherein the conjugate of Formula I is orally administered substantially contemporaneously with the ingestion of a meal by the patient.
60. A method according to Claim 49, wherein the conjugate of Formula I is orally administered less than about one hour after ingestion of a meal by the patient.
61. A method according to Claim 49, wherein the insulin polypeptide is insulin.
62. A method according to Claim 61, wherein the oligomer is coupled to the lysine at the B29 position of the insulin.
63. A method according to Claim 49, wherein the insulin polypeptide is an insulin analog selected from the group consisting of Gly A21 insulin, human; Gly A21 Gln B3 insulin, human; Ala A21 insulin, human; Ala A21 Gln B3 insulin, human; Gln B3 insulin, human; Gln B30 insulin, human; Gly A21 Glu B30 insulin, human; Gly A21 Gln B3 Glu B30 insulin, human; Gln B3 Glu B30 insulin, human; Asp B28 insulin, human; Lys B28 insulin, human; Leu B28 insulin, human;
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
64. A method according to Claim 49, wherein the conjugate of Formula I is present as a substantially monodispersed mixture.
65. A method according to Claim 49, wherein the conjugate of Formula I is present as a monodispersed mixture.
66. A method according to Claim 49, wherein the conjugate of Formula I is amphiphilically balanced.
67. A method according to Claim 49, wherein the effective amount of the conjugate of Formula I is present in a pharmaceutical composition.
68. A method according to Claim 49, wherein B is selected from the group consisting of an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety and a covalent bond.
69. A method according to Claim 49, wherein L is selected from the group consisting of alkyl moieties and fatty acid moieties.
70. A method according to Claim 49, wherein G, G' and G" are individually selected from the group consisting of sugar moieties, cholesterol, and glycerine moieties.
71. A method according to Claim 49, wherein T is selected from the group consisting of alkyl and alkoxy.
72. A method according to Claim 49, wherein the polyalkylene glycol moiety is a polyethylene glycol moiety.
73. A method according to Claim 72, wherein the polyethylene glycol moiety has between l and 50 polyethylene glycol subunits.
74. A method according to Claim 72, wherein the polyethylene glycol moiety has between 3 and 50 polyethylene glycol subunits.
75. A method according to Claim 72, wherein the polyethylene glycol moiety has between 2 and 10 polyethylene glycol subunits.
76. A method according to Claim 72, wherein the polyethylene glycol moiety has between 4 and 10 polyethylene glycol subunits.
77. A method according to Claim 72, wherein the polyethylene glycol moiety has at least 2 polyethylene glycol subunits.
78. A method according to Claim 49, wherein the lipophilic moiety is an alkyl or a fatty acid moiety.
79. A method according to Claim 78, wherein the lipophilic moiety has between and 28 carbon atoms.
80. A method according to Claim 78, wherein the lipophilic moiety has between and 24 carbon atoms.
81. A method according to Claim 78, wherein the lipophilic moiety has between and 18 carbon atoms.
82. A method according to Claim 78, wherein the lipophilic moiety has between and 12 carbon atoms.
83. A method according to Claim 78, wherein the lipophilic moiety has between and 7 carbon atoms.
84. A method according to Claim 78, wherein the lipophilic moiety has between and 14 carbon atoms.
85. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula II:
Insulin polypeptide ~ X(CH2)m Y(C2H4O)n R (II) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety or a covalent bond;
Y is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the conjugate of Formula II is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula II:
Insulin polypeptide ~ X(CH2)m Y(C2H4O)n R (II) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety or a covalent bond;
Y is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the conjugate of Formula II is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
86. A method according to Claim 85, wherein the oral administration of the effective amount of the conjugate of Formula II provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 30 minutes of administration.
87. A method according to Claim 85, wherein the effective amount of the conjugate of Formula II is between about 0.05 and 10 mg per kilogram body weight.
88. A method according to Claim 85, wherein the oral administration of the effective amount of the conjugate of Formula II provides a maximum insulin drug concentration in peripheral blood within about 60 minutes after administration.
89. A method according to Claim 85, wherein the oral administration of the effective amount of the conjugate of Formula II stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
90. A method according to Claim 85, wherein the conjugate of Formula II clears the bloodstream of the patient within about 4 hours following administration.
91. A method according to Claim 85, wherein the administration of the effective amount of the conjugate of Formula II reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
92. A method according to Claim 91, wherein the reduction in hepatic glucose production occurs within about 90 minutes after administration.
93. A method according to Claim 85, wherein the conjugate of Formula II is orally administered such that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes after ingestion of the meal by the patient.
94. A method according to Claim 85, wherein the conjugate of Formula II is orally administered less than about one hour prior to ingestion of a meal by the patient.
95. A method according to Claim 85, wherein the conjugate of Formula II is orally administered substantially contemporaneously with the ingestion of a meal by the patient.
96. A method according to Claim 85, wherein the conjugate of Formula II is orally administered less than one about hour after ingestion of a meal by the patient.
97. A method according to Claim 85, wherein the insulin polypeptide is insulin.
98. A method according to Claim 97, wherein the oligomer is coupled to the lysine at the B29 position of the insulin.
99. A method according to Claim 85, wherein the insulin polypeptide is an insulin analog selected from the group consisting of Gly A21 insulin, human; Gly A21 Gln B3 insulin, human; Ala A21 insulin, human; Ala A21 Gln B3 insulin, human; Gln B3 insulin, human; Gln B30 insulin, human; Gly A21 Glu B30 insulin, human; Gly A21 Gln B3 Glu B30 insulin, human; Gln B3 Glu B30 insulin, human; Asp B28 insulin, human; Lys B28 insulin, human; Leu B28 insulin, human;
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
100. A method according to Claim 85, wherein the conjugate of Formula II is present as a substantially monodispersed mixture.
101. A method according to Claim 85, wherein the conjugate of Formula II is present as a monodispersed mixture.
102. A method according to Claim 85, wherein the conjugate of Formula II is amphiphilically balanced.
103. A method according to Claim 85, wherein the effective amount of the conjugate of Formula II is present in a pharmaceutical composition.
104. A method according to Claim 85, wherein the polyalkylene glycol moiety is a polyethylene glycol moiety.
105. A method according to Claim 85, wherein m is between 3 and 16.
106. A method according to Claim 85, wherein m is between 4 and 14.
107. A method according to Claim 85, wherein m is between 5 and 10.
108. A method according to Claim 85, wherein n is between 3 and 18.
109. A method according to Claim 85, wherein n is between 4 and 14.
110. A method according to Claim 85, wherein n is between 5 and 10.
111. A method according to Claim 85, wherein R is lower alkyl.
112. A method according to Claim 85, wherein R is C1 to C3 alkyl.
113. A method according to Claim $5, wherein R is methyl.
114. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III:
Insulin polypeptide ~ X(CH2)m(OC2H4)n OR (III) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between l and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantine, an alcohol moiety, or a fatty acid moiety;
to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the conjugate of Formula III is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III:
Insulin polypeptide ~ X(CH2)m(OC2H4)n OR (III) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between l and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantine, an alcohol moiety, or a fatty acid moiety;
to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the conjugate of Formula III is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
115. A method according to Claim 114, wherein the oral administration of the effective amount of the conjugate of Formula III provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 30 minutes of administration.
116. A method according to Claim 114, wherein the effective amount of the conjugate of Formula III is between about 0.05 and 10 mg per kilogram body weight.
117. A method according to Claim 114, wherein the oral administration of the effective amount of the conjugate of Formula III provides a maximum insulin drug concentration in peripheral blood within about 60 minutes after administration.
118. A method according to Claim 114, wherein the oral administration of the effective amount of the conjugate of Formula III stabilizes peripheral glucose concentration to within about+/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
119. A method according to Claim 114, wherein the conjugate of Formula III
clears the bloodstream of the patient within about 4 hours following administration.
clears the bloodstream of the patient within about 4 hours following administration.
120. A method according to Claim 114, wherein the administration of the effective amount of the conjugate of Formula III reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
121. A method according to Claim 120, wherein the reduction in hepatic glucose production occurs within about 90 minutes after administration.
122. A method according to Claim 114, wherein the conjugate of Formula III is orally administered such that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes after ingestion of the meal by the patient.
123. A method according to Claim 114, wherein the conjugate of Formula III is orally administered less than about one hour prior to ingestion of a meal by the patient.
124. A method according to Claim 114, wherein the conjugate of Formula III is orally administered substantially contemporaneously with the ingestion of a meal by the patient.
125. A method according to Claim 114, wherein the conjugate of Formula III is orally administered less than about one hour after ingestion of a meal by the patient.
126. A method according to Claim 114, wherein the insulin polypeptide is insulin.
127. A method according to Claim 126, wherein the oligomer is coupled to the lysine at the B29 position of the insulin.
128. A method according to Claim 114, wherein the insulin polypeptide is an insulin analog selected from the group consisting of Gly A21 insulin, human;
Gly A21 Gln B3 insulin, human; Ala A21 insulin, human; Ala A21 Gln B3 insulin, human; Gln B3 insulin, human;
Gln B30 insulin, human; Gly A21 Glu B30 insulin, human; Gly A21 Gln B3 Glu B30 insulin, human;
Gln B3 Glu B30 insulin, human; Asp B28 insulin, human; Lys B28 insulin, human;
Leu B28 insulin, human; Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
Gly A21 Gln B3 insulin, human; Ala A21 insulin, human; Ala A21 Gln B3 insulin, human; Gln B3 insulin, human;
Gln B30 insulin, human; Gly A21 Glu B30 insulin, human; Gly A21 Gln B3 Glu B30 insulin, human;
Gln B3 Glu B30 insulin, human; Asp B28 insulin, human; Lys B28 insulin, human;
Leu B28 insulin, human; Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
129. A method according to Claim 114, wherein the conjugate of Formula III is present as a substantially monodispersed mixture.
130. A method according to Claim 114, wherein the conjugate of Formula III is present as a monodispersed mixture.
131. A method according to Claim 114, wherein the conjugate of Formula III is amphiphilically balanced.
132. A method according to Claim 114, wherein the effective amount of the conjugate of Formula III is present in a pharmaceutical composition.
133. A method according to Claim 114, wherein m is between 3 and 16.
134. A method according to Claim 114, wherein m is between 4 and 14.
135. A method according to Claim 114, wherein m is between 5 and 10.
136. A method according to Claim 114, wherein n is between 3 and 18.
137. A method according to Claim 114, wherein n is between 4 and 14.
138. A method according to Claim 114, wherein n is between 5 and 10.
139. A method according to Claim 114, wherein R is lower alkyl.
140. A method according to Claim 114, wherein R is C1 to C3 alkyl.
141. A method according to Claim 114, wherein R is methyl.
142. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula IV:
wherein:
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the conjugate of Formula IV is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula IV:
wherein:
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the conjugate of Formula IV is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
143. A method according to Claim 142, wherein the oral administration of the effective amount of the conjugate of Formula IV provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 30 minutes of administration.
144. A method according to Claim 142, wherein the effective amount of the conjugate of Formula IV is between about 0.05 and about 10 mg per kilogram body weight.
145. A method according to Claim 142, wherein the oral administration of the effective amount of the conjugate of Formula IV provides a maximum insulin drug concentration in peripheral blood within about 60 minutes after administration.
146. A method according to Claim 142, wherein the oral administration of the effective amount of the conjugate of Formula IV stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
147. A method according to Claim 142, wherein the conjugate of Formula IV
clears the bloodstream of the patient within about 4 hours following administration.
clears the bloodstream of the patient within about 4 hours following administration.
148. A method according to Claim 142, wherein the administration of the effective amount of the conjugate of Formula IV reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
149. A method according to Claim 148, wherein the reduction in hepatic glucose production occurs within about 90 minutes after administration.
150. A method according to Claim 142, wherein the conjugate of Formula IV is orally administered such that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes after ingestion of the meal by the patient.
151. A method according to Claim 142, wherein the conjugate of Formula IV is orally administered less than about one hour prior to ingestion of a meal by the patient.
152. A method according to Claim 142, wherein the conjugate of Formula IV is orally administered substantially contemporaneously with the ingestion of a meal by the patient.
153. A method according to Claim 142, wherein the conjugate of Formula IV is orally administered less than about one hour after ingestion of a meal by the patient.
154. A method according to Claim 142, wherein the insulin polypeptide is insulin.
155. A method according to Claim 154, wherein the oligomer is coupled to the lysine at the B29 position of the insulin.
156. A method according to Claim 142, wherein the insulin polypeptide is an insulin analog selected from the group consisting of Gly A21 insulin, human;
Gly A21 Gln B3 insulin, human; Ala A21 insulin, human; Ala A21 Gln B3 insulin, human; Gln B3 insulin, human;
Gln B3 insulin, human; Gly A21 Glu B3 insulin, human; Gly A21 Gln B3 Glu B30 insulin, human;
Gln B3 Glu B30 insulin, human; Asp B28 insulin, human; Lys B28 insulin, human;
Leu B28 insulin, human; Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
Gly A21 Gln B3 insulin, human; Ala A21 insulin, human; Ala A21 Gln B3 insulin, human; Gln B3 insulin, human;
Gln B3 insulin, human; Gly A21 Glu B3 insulin, human; Gly A21 Gln B3 Glu B30 insulin, human;
Gln B3 Glu B30 insulin, human; Asp B28 insulin, human; Lys B28 insulin, human;
Leu B28 insulin, human; Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
157. A method according to Claim 142, wherein the conjugate of Formula IV is present as a substantially monodispersed mixture.
158. A method according to Claim 142, wherein the conjugate of Formula IV is present as a monodispersed mixture.
159. A method according to Claim 142, wherein the conjugate of Formula IV is amphiphilically balanced.
160. A method according to Claim 142, wherein the effective amount of the conjugate of Formula IV is present in a pharmaceutical composition.
161. A method according to Claim 142, wherein m is between 3 and 16.
162. A method according to Claim 142, wherein m is between 4 and 14.
163. A method according to Claim 142, wherein m is between 5 and 10.
164. A method according to Claim 142, wherein n is between 3 and 18.
165. A method according to Claim 142, wherein n is between 4 and 14.
166. A method according to Claim 142, wherein n is between 5 and 10.
167. A method according to Claim 142, wherein R is lower alkyl.
168. A method according to Claim 142, wherein R is C1 to C3 alkyl.
169. A method according to Claim 142, wherein R is methyl.
170. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula V:
to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the conjugate of Formula V is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula V:
to the patient within one hour of ingestion of a meal by the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the conjugate of Formula V is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
171. A method according to Claim 170, wherein the oral administration of the effective amount of the conjugate of Formula V provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 30 minutes of administration.
172. A method according to Claim 170, wherein the effective amount of the conjugate of Formula V is between about 0.05 and 10 mg per kilogram body weight.
173. A method according to Claim 170, wherein the oral administration of the effective amount of the conjugate of Formula V provides a maximum insulin drug concentration in peripheral blood within about 60 minutes after administration.
174. A method according to Claim 170, wherein the oral administration of the effective amount of the conjugate of Formula V stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
175. A method according to Claim 170, wherein the conjugate of Formula V
clears the bloodstream of the patient within about 4 hours following administration.
clears the bloodstream of the patient within about 4 hours following administration.
176. A method according to Claim 170, wherein the administration of the effective amount of the conjugate of Formula V reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without .
administration.
administration.
177. A method according to Claim 176, wherein the reduction in hepatic glucose production occurs within about 90 minutes after administration.
178. A method according to Claim 170, wherein the conjugate of Formula V is orally administered such that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes after ingestion of the meal by the patient.
179. A method according to Claim 170, wherein the conjugate of Formula V is orally administered less than about one hour prior to ingestion of a meal by the patient.
180. A method according to Claim 170, wherein the conjugate of Formula V is orally administered substantially contemporaneously with the ingestion of a meal by the patient.
181. A method according to Claim 170, wherein the conjugate of Formula V is orally administered less than about one hour after ingestion of a meal by the patient.
182. A method according to Claim 170, wherein the insulin polypeptide is insulin.
183. A method according to Claim 182, wherein the oligomer is coupled to the lysine at the B29 position of the insulin.
184. A method according to Claim 170, wherein the insulin polypeptide is an insulin analog selected from the group consisting of Gly A21 insulin, human;
Gly A21 Gln B3 insulin, human; Ala A21 insulin, human; Ala A21 Gln B3 insulin, human; Gln B3 insulin, human;
Gln B30 insulin, human; Gly A21 Glu B30 insulin, human; Gly A21 Gln B3 Glu B30 insulin, human;
Gln B3 Glu B30 insulin, human; Asp B28 insulin, human; lys B28 insulin, human;
Leu B28 insulin, human; Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
Gly A21 Gln B3 insulin, human; Ala A21 insulin, human; Ala A21 Gln B3 insulin, human; Gln B3 insulin, human;
Gln B30 insulin, human; Gly A21 Glu B30 insulin, human; Gly A21 Gln B3 Glu B30 insulin, human;
Gln B3 Glu B30 insulin, human; Asp B28 insulin, human; lys B28 insulin, human;
Leu B28 insulin, human; Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
185. A method according to Claim 170, wherein the conjugate of Formula V is present as a substantially monodispersed mixture.
186. A method according to Claim 170, wherein the conjugate of Formula V is present as a monodispersed mixture.
187. A method according to Claim 170, wherein the effective amount of the conjugate of Formula V is present in a pharmaceutical composition.
188. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide derivative to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide derivative is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
orally administering an effective amount of an insulin polypeptide derivative to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide derivative is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
189. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide derivative to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide derivative is administered so that it stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
orally administering an effective amount of an insulin polypeptide derivative to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide derivative is administered so that it stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
190. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide derivative to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide derivative is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
orally administering an effective amount of an insulin polypeptide derivative to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide derivative is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
191. A method according to Claim 190, wherein the reduction in hepatic glucose production occurs within about 90 minutes after administration.
192. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide derivative to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide derivative is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes after ingestion of the meal by the patient.
orally administering an effective amount of an insulin polypeptide derivative to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide derivative is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes after ingestion of the meal by the patient.
193. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an amphiphilically-balanced insulin polypeptide-oligomer conjugate to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and about 1,000 U/ml within about 60 minutes of administration.
orally administering an effective amount of an amphiphilically-balanced insulin polypeptide-oligomer conjugate to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and about 1,000 U/ml within about 60 minutes of administration.
194. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an amphiphilically-balanced insulin polypeptide-oligomer conjugate to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
orally administering an effective amount of an amphiphilically-balanced insulin polypeptide-oligomer conjugate to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
195. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an amphiphilically-balanced insulin polypeptide-oligomer conjugate to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
orally administering an effective amount of an amphiphilically-balanced insulin polypeptide-oligomer conjugate to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
196. A method according to Claim I95, wherein the reduction in hepatic glucose production occurs within about 90 minutes after administration.
197. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an amphiphilically-balanced insulin polypeptide-oligomer conjugate to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes of ingestion of the meal by the patient.
orally administering an effective amount of an amphiphilically-balanced insulin polypeptide-oligomer conjugate to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes of ingestion of the meal by the patient.
198. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula I:
Insulin Polypeptide-B-L j-G k-R-G'm-R'-G" n-T (I) wherein:
B is a bonding moiety selected from the group consisting of an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety and a covalent bond;
L is a linker moiety selected from the group consisting of alkyl moieties and fatty acid moieties;
G, G' and G" are spacer moieties individually selected from the group consisting of sugar moieties, cholesterol, and glycerine moieties;
R is a lipophilic moiety and R' is a polyalkylene glycol moiety, or R' is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety selected from the group consisting of alkyl and alkoxy; and j, k, m and n are individually 0 or 1;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula I:
Insulin Polypeptide-B-L j-G k-R-G'm-R'-G" n-T (I) wherein:
B is a bonding moiety selected from the group consisting of an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety and a covalent bond;
L is a linker moiety selected from the group consisting of alkyl moieties and fatty acid moieties;
G, G' and G" are spacer moieties individually selected from the group consisting of sugar moieties, cholesterol, and glycerine moieties;
R is a lipophilic moiety and R' is a polyalkylene glycol moiety, or R' is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety selected from the group consisting of alkyl and alkoxy; and j, k, m and n are individually 0 or 1;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
199. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula I:
Insulin Polypeptide-B-L j-G k-R-G'm R'-G"n-T (I) wherein:
B is a bonding moiety selected from the group consisting of an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, and a covalent bond;
L is a linker moiety selected from the group consisting of alkyl moieties and fatty acid moieties;
G, G' and G" are spacer moieties individually selected from the group consisting of sugar moieties, cholesterol, and glycerine moieties;
R is a lipophilic moiety and R' is a polyalkylene glycol moiety, or R' is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety selected from the group consisting of alkyl and alkoxy; and j, k, m and n are individually 0 or 1;
to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula I:
Insulin Polypeptide-B-L j-G k-R-G'm R'-G"n-T (I) wherein:
B is a bonding moiety selected from the group consisting of an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, and a covalent bond;
L is a linker moiety selected from the group consisting of alkyl moieties and fatty acid moieties;
G, G' and G" are spacer moieties individually selected from the group consisting of sugar moieties, cholesterol, and glycerine moieties;
R is a lipophilic moiety and R' is a polyalkylene glycol moiety, or R' is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety selected from the group consisting of alkyl and alkoxy; and j, k, m and n are individually 0 or 1;
to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
200. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula I:
Insulin Polypeptide-B-L j-G k-R-G'm-R'-G"n-T (I) wherein:
B is a bonding moiety selected from the group consisting of an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, and a covalent bond;
L is a linker moiety selected from the group consisting of alkyl moieties and fatty acid moieties;
G, G' and G" are spacer moieties individually selected from the group consisting of sugar moieties, cholesterol, and glycerine moieties;
R is a lipophilic moiety and R' is a polyalkylene glycol moiety, or R' is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety selected from the group consisting of alkyl and alkoxy; and j, k, m and n are individually 0 or 1;
to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula I:
Insulin Polypeptide-B-L j-G k-R-G'm-R'-G"n-T (I) wherein:
B is a bonding moiety selected from the group consisting of an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, and a covalent bond;
L is a linker moiety selected from the group consisting of alkyl moieties and fatty acid moieties;
G, G' and G" are spacer moieties individually selected from the group consisting of sugar moieties, cholesterol, and glycerine moieties;
R is a lipophilic moiety and R' is a polyalkylene glycol moiety, or R' is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety selected from the group consisting of alkyl and alkoxy; and j, k, m and n are individually 0 or 1;
to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
201. A method according to Claim 200, wherein the reduction in hepatic glucose production occurs within about 90 minutes after administration.
202. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula I:
Insulin Polypeptide-B-L j-G k-R-G'm R'-G"n-T (I) wherein:
B is a bonding moiety selected from the group consisting of an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, and a covalent bond;
L is a linker moiety selected from the group consisting of alkyl moieties and fatty acid moieties;
G, G' and G" are spacer moieties individually selected from the group consisting of sugar moieties, cholesterol, and glycerine moieties;
R is a lipophilic moiety and R' is a polyalkylene glycol moiety, or R' is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety selected from the group consisting of alkyl and alkoxy; and j, k, m and n are individually 0 or 1;
to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes of ingestion of the meal by the patient.
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula I:
Insulin Polypeptide-B-L j-G k-R-G'm R'-G"n-T (I) wherein:
B is a bonding moiety selected from the group consisting of an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, and a covalent bond;
L is a linker moiety selected from the group consisting of alkyl moieties and fatty acid moieties;
G, G' and G" are spacer moieties individually selected from the group consisting of sugar moieties, cholesterol, and glycerine moieties;
R is a lipophilic moiety and R' is a polyalkylene glycol moiety, or R' is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety selected from the group consisting of alkyl and alkoxy; and j, k, m and n are individually 0 or 1;
to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes of ingestion of the meal by the patient.
203. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula II:
Insulin polypeptide X(CH2)m Y(C2H4O)n R (II) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thin-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
Y is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient tin order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula II:
Insulin polypeptide X(CH2)m Y(C2H4O)n R (II) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thin-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
Y is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient tin order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
204. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula II:
Insulin polypeptide X(CH2)m Y(C2H40)"R (II) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
Y is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula II:
Insulin polypeptide X(CH2)m Y(C2H40)"R (II) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
Y is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
205. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula II:
Insulin polypeptide X(CH2)m Y(C2H4O)n R (II) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
Y is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula II:
Insulin polypeptide X(CH2)m Y(C2H4O)n R (II) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
Y is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
206. A method according to Claim 205, wherein the reduction in hepatic glucose production occurs within about 90 minutes after administration.
207. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula II:
Insulin polypeptide X(CH2)m Y(C2H4O)n R (II) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
Y is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes of ingestion of the meal by the patient.
orally administering an effective amount of an insulin polypeptide-oligomer conjugate comprising the structure of Formula II:
Insulin polypeptide X(CH2)m Y(C2H4O)n R (II) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
Y is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes of ingestion of the meal by the patient.
208. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III:
Insulin polypeptide X(CH2)m(OC2H4)n OR (III) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III:
Insulin polypeptide X(CH2)m(OC2H4)n OR (III) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
209. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III:
Insulin polypeptide~X(CH2)m(OC2H4)n OR (III) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III:
Insulin polypeptide~X(CH2)m(OC2H4)n OR (III) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
210. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III:
Insulin polypeptide~X(GH2)m(OC2H4)n OR (III) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III:
Insulin polypeptide~X(GH2)m(OC2H4)n OR (III) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
211. A method according to Claim 210, wherein the reduction in hepatic glucose production occurs within about 90 minutes after administration.
212. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III:
Insulin polypeptide~X(CH2)m(OC2H4)n OR (III) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thin-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes of ingestion of the meal by the patient.
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III:
Insulin polypeptide~X(CH2)m(OC2H4)n OR (III) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thin-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes of ingestion of the meal by the patient.
213. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula IV:
wherein:
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula IV:
wherein:
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
214. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula IV:
wherein:
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula IV:
wherein:
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
215. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula IV:
wherein:
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula IV:
wherein:
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
216. A method according to Claim 215, wherein the reduction in hepatic glucose production occurs within about 90 minutes after administration.
217. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula IV:
wherein:
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes of ingestion of the meal by the patient.
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula IV:
wherein:
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes of ingestion of the meal by the patient.
218. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula V:
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula V:
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
219. A method according to Claim 218, wherein the insulin polypeptide is insulin.
220. A method according to Claim 219, wherein the oligomer is coupled to the lysine at the B29 position of the insulin.
221. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula V:
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula V:
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/- 50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration.
222. A method according to Claim 221, wherein the insulin polypeptide is insulin.
223. A method according to Claim 222, wherein the oligomer is coupled to the lysine at the B29 position of the insulin.
224. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula V:
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula V:
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the patient without administration.
225. A method according to Claim 224, wherein the reduction in hepatic glucose production occurs within about 90 minutes after administration.
226. A method according to Claim 224, wherein the insulin polypeptide is insulin.
227. A method according to Claim 226, wherein the oligomer is coupled to the lysine at the B29 position of the insulin.
228. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula V:
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes after ingestion of the meal by the patient.
orally administering an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula V:
to the patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes after ingestion of the meal by the patient.
229. A method according to Claim 228, wherein the insulin polypeptide is insulin.
230. A method according to Claim 229, wherein the oligomer is coupled to the lysine at the B29 position of the insulin.
231. The use of an insulin polypeptide derivative for the preparation of an orally administrable medicament for the treatment of diabetes mellitus.
232. The use according to Claim 231, wherein the insulin polypeptide derivative is an insulin polypeptide-oligomer conjugate.
233. The use according to Claim 232, wherein the insulin polypeptide-oligomer conjugate is an amphiphilically balanced insulin polypeptide-oligomer conjugate.
234. The use of an amphiphilically-balanced insulin polypeptide-oligomer conjugate for the preparation of an orally administrable medicament for the treatment of diabetes mellitus.
235. The use according to Claim 234, wherein the insulin polypeptide is insulin.
236. The use according to Claim 235, wherein the oligomer is coupled to the lysine at the B29 position of the insulin.
237. The use according to Claim 234, wherein the insulin polypeptide is an insulin analog selected from the group consisting of Gly A21 insulin, human; Gly A21 Gln B3 insulin, human; Ala A21 insulin, human; Ala A21 Gln B3 insulin, human; Gln B3 insulin, human; Gln B30 insulin, human; Gly A21 Glu B30 insulin, human; Gly A21 Gln B3 Glu B30 insulin, human; Gln B3 Glu B30 insulin, human; Asp B28 insulin, human; Lys B28 insulin, human; Leu B28 insulin, human;
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
238. The use according to Claim 234, wherein the amphiphilically-balanced insulin polypeptide oligomer conjugate is present as a substantially monodispersed mixture.
239. The use according to Claim 234, wherein the amphphilically-balanced insulin polypeptide-oligomer conjugate is present as a monodispersed mixture.
240. The use according to Claim 234, wherein the effective amount of the amphiphilically-balanced insulin polypeptide-oligomer conjugate is present in a pharmaceutical composition.
241. The use according to Claim 234, wherein the amphiphilically-balanced insulin polypeptide-oligomer conjugate comprises a hydrophilic moiety and a lipophilic moiety.
242. The use according to Claim 241, wherein the hydrophilic moiety is a polyalkylene glycol moiety.
243. The use according to Claim 241, wherein the polyalkylene glycol moiety is a polyethylene glycol moiety.
244. The use according to Claim 241, wherein the polyalkylene glycol moiety has between 1 and 50 polyalkylene glycol subunits.
245. The use according to Claim 241, wherein the polyalkylene glycol moiety has between 3 and 50 polyalkylene glycol subunits.
246. The use according to Claim 241, wherein the polyalkylene glycol moiety has between 2 and 10 polyalkylene glycol subunits.
247. The use according to Claim 241, wherein the polyalkylene glycol moiety has between 4 and 10 polyalkylene glycol subunits.
248. The use according to Claim 241, wherein the polyalkylene glycol moiety has at least 2 polyalkylene glycol subunits.
249. The use according to Claim 241, wherein the lipophilic moiety is an alkyl or fatty acid moiety.
250. The use according to Claim 241, wherein the lipophilic moiety has between and 28 carbon atoms.
251. The use according to Claim 241, wherein the lipophilic moiety has between and 24 carbon atoms.
252. The use according to Claim 241, wherein the lipophilic moiety has between and 18 carbon atoms.
253. The use according to Claim 241, wherein the lipophilic moiety has between and 12 carbon atoms.
254. The use according to Claim 241, wherein the lipophilic moiety has between and 7 carbon atoms.
255. The use according to Claim 241, wherein the lipophilic moiety has between and 14 carbon atoms.
256. The use of an insulin polypeptide-oligomer conjugate comprising the structure of Formula I:
Insulin Polypeptide~B~L j~G k~R~G'm~R'~G"n~T (I) wherein:
B is a bonding moiety;
L is a linker moiety;
G, G' and G" are individually selected spacer moieties;
R is a lipophilic moiety and R' is a polyalkylene glycol moiety, or R' is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety; and j, k, m and n are individually 0 or 1;
for the preparation of an orally administrable medicament for the treatment of diabetes mellitus.
Insulin Polypeptide~B~L j~G k~R~G'm~R'~G"n~T (I) wherein:
B is a bonding moiety;
L is a linker moiety;
G, G' and G" are individually selected spacer moieties;
R is a lipophilic moiety and R' is a polyalkylene glycol moiety, or R' is the lipophilic moiety and R is the polyalkylene glycol moiety;
T is a terminating moiety; and j, k, m and n are individually 0 or 1;
for the preparation of an orally administrable medicament for the treatment of diabetes mellitus.
257. The use according to Claim 256, wherein the insulin polypeptide is insulin.
258. The use according to Claim 257, wherein the oligomer is coupled to the lysine at the B29 position of the insulin.
259. The use according to Claim 256, wherein the insulin polypeptide is an insulin analog selected from the group consisting of Gly A21 insulin, human; Gly A21 Gln B3 insulin, human; Ala A21 insulin, human; Ala A21 Gln B3 insulin, human; Gln B3 insulin, human; Gln B30 insulin, human; Gly A21 Glu B30 insulin, human; Gly A21 Gln B3 Glu B30 insulin, human; Gln B3 Glu B30 insulin, human; Asp B28 insulin, human; Lys B28 insulin, human; Leu B28 insulin, human;
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
260. The use according to Claim 256, wherein the conjugate of Formula I is present as a substantially monodispersed mixture.
261. The use according to Claim 256, wherein the conjugate of Formula I is present as a monodispersed mixture.
262. The use according to Claim 256, wherein the conjugate of Formula I is amphiphilically balanced.
263. The use according to Claim 256, wherein the effective amount of the conjugate of Formula I is present in a pharmaceutical composition.
264. The use according to Claim 256, wherein B is selected from the group consisting of an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thin-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety and a covalent bond.
265. The use according to Claim 256, wherein L is selected from the group consisting of alkyl moieties and fatty acid moieties.
266. The use according to Claim 256, wherein G, G' and G" are individually selected from the group consisting of sugar moieties, cholesterol, and glycerine moieties.
267. The use according to Claim 256, wherein T is selected from the group consisting of alkyl and alkoxy.
268. The use according to Claim 256, wherein the polyalkylene glycol moiety is a polyethylene glycol moiety.
269. The use according to Claim 268, wherein the polyethylene glycol moiety has between 1 and 50 polyethylene glycol subunits.
270. The use according to Claim 268, wherein the polyethylene glycol moiety has between 3 and 50 polyethylene glycol subunits.
271. The use according to Claim 268, wherein the polyethylene glycol moiety has between 2 and 10 polyethylene glycol subunits.
272. The use according to Claim 268, wherein the polyethylene glycol moiety has between 4 and 10 polyethylene glycol subunits.
273. The use according to Claim 268, wherein the polyethylene glycol moiety has at least 2 polyethylene glycol subunits.
274. The use according to Claim 256, wherein the lipophilic moiety is an alkyl or a fatty acid moiety.
275. The use according to Claim 274, wherein the lipophilic moiety has between and 28 carbon atoms.
276. The use according to Claim 274, wherein the lipophilic moiety has between and 24 carbon atoms.
277. The use according to Claim 274, wherein the lipophilic moiety has between and 18 carbon atoms.
278. The use according to Claim 274, wherein the lipophilic moiety has between and 12 carbon atoms.
279. The use according to Claim 274, wherein the lipophilic moiety has between and 7 carbon atoms.
280. The use according to Claim 274, wherein the lipophilic moiety has between and 14 carbon atoms.
281. The use of an insulin polypeptide-oligomer conjugate comprising the structure of Formula II:
Insulin polypeptide~X(CH2)m Y(C2H4O)n R (II) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety or a covalent bond;
Y is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantine, an alcohol moiety, or a fatty acid moiety;
for the preparation of an orally administrable medicament for the treatment of diabetes mellitus.
Insulin polypeptide~X(CH2)m Y(C2H4O)n R (II) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety or a covalent bond;
Y is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantine, an alcohol moiety, or a fatty acid moiety;
for the preparation of an orally administrable medicament for the treatment of diabetes mellitus.
282. The use according to Claim 281, wherein the insulin polypeptide is insulin.
283. The use according to Claim 282, wherein the oligomer is coupled to the lysine at the B29 position of the insulin.
284. The use according to Claim 281, wherein the insulin polypeptide is an insulin analog selected from the group consisting of Gly A21 insulin, human; Gly A21 Gln B3 insulin, human; Ala A21 insulin, human; Ala A21 Gln B3 insulin, human; Gln B3 insulin, human; Gln B30 insulin, human; Gly A21 Glu B30 insulin, human; Gly A21 Gln B3 Glu B30 insulin, human; Gln B3 Glu B30 insulin, human; Asp B28 insulin, human; Lys B28 insulin, human; Leu B28 insulin, human;
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
285. The use according to Claim 281, wherein the conjugate of Formula II is present as a substantially monodispersed mixture.
286. The use according to Claim 281, wherein the conjugate of Formula II is present as a monodispersed mixture.
287. The use according to Claim 281, wherein the conjugate of Formula II is amphiphilically balanced.
288. The use according to Claim 281, wherein the effective amount of the conjugate of Formula II is present in a pharmaceutical, composition.
289. The use according to Claim 281, wherein the polyalkylene glycol moiety is a polyethylene glycol moiety.
290. The use according to Claim 281, wherein m is between 3 and 16.
291. The use according to Claim 281, wherein m is between 4 and 14.
292. The use according to Claim 281, wherein m is between 5 and 10.
293. The use according to Claim 281, wherein n is between 3 and 18.
294. The use according to Claim 281, wherein n is between 4 and 14.
295. The use according to Claim 281, wherein n is between 5 and 10.
296. The use according to Claim 281, wherein R is lower alkyl.
297. The use according to Claim 281, wherein R is C1 to C3 alkyl.
298. The use according to Claim 281, wherein R is methyl.
299. The use of an insulin polypeptide-oligomer conjugate comprising the structure of Formula III:
Insulin polypeptide~X(CH2)m(OC2H4)n OR (III) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
for the preparation of an orally administrable medicament for the treatment of diabetes mellitus.
Insulin polypeptide~X(CH2)m(OC2H4)n OR (III) wherein:
X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
for the preparation of an orally administrable medicament for the treatment of diabetes mellitus.
300. The use according to Claim 299, wherein the insulin polypeptide is insulin.
301. The use according to Claim 300, wherein the oligomer is coupled to the lysine at the B29 position of the insulin.
302. The use according to Claim 299, wherein the insulin polypeptide is an insulin analog selected from the group consisting of Gly A21 insulin, human; Gly A21 Gln B3 insulin, human; Ala A21 insulin, human; Ala A21 Gln B3 insulin, human; Gln B3 insulin, human; Gln B30 insulin, human; Gly A21 Glu B30 insulin, human; Gly A21 Gln B3 Glu B30 insulin, human; Gln B3 Glu B30 insulin, human; Asp B28 insulin, human; Lys B28 insulin, human; Leu B28 insulin, human;
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
303. The use according to Claim 299, wherein the conjugate of Formula III is present as a substantially monodispersed mixture.
304. The use according to Claim 299, wherein the conjugate of Formula III is present as a monodispersed mixture.
305. The use according to Claim 299, wherein the conjugate of Formula III is amphiphilically balanced.
306. The use according to Claim 299, wherein the effective amount of the conjugate of Formula III is present in a pharmaceutical composition.
307. The use according to Claim 299, wherein m is between 3 and 16.
308. The use according to Claim 299, wherein m is between 4 and 14.
309. The use according to Claim 299, wherein m is between 5 and 10.
310. The use according to Claim 299, wherein n is between 3 and 18.
311. The use according to Claim 299, wherein n is between 4 and 14.
312. The use according to Claim 299, wherein n is between 5 and 10.
313. The use according to Claim 299, wherein R is lower alkyl.
314. The use according to Claim 299, wherein R is C1 to C3 alkyl.
315. The use according to Claim 299, wherein R is methyl.
316. The use of an insulin polypeptide-oligomer conjugate comprising the structure of Formula IV:
wherein:
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
for the preparation of an orally administrable medicament for the treatment of diabetes mellitus.
wherein:
m is between 1 and 24;
n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
for the preparation of an orally administrable medicament for the treatment of diabetes mellitus.
317. The use according to Claim 316, wherein the insulin polypeptide is insulin.
318. The use according to Claim 317, wherein the oligomer is coupled to the lysine at the B29 position of the insulin.
319. The use according to Claim 316, wherein the insulin polypeptide is an insulin analog selected from the group consisting of Gly A21 insulin, human; Gly A21 Gln B3 insulin, human; Ala A21 insulin, human; Ala A21 Gln B3 insulin, human; Gln B3 insulin, human; Gln B30 insulin, human; Gly A21 Glu B30 insulin, human; Gly A21 Gln B3 Glu B30 insulin, human; Gln B3 Glu B30 insulin, human; Asp B28 insulin, human; Lys B28 insulin, human; Leu B28 insulin, human;
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
320. The use according to Claim 316, wherein the conjugate of Formula IV is present as a substantially monodispersed mixture.
321. The use according to Claim 316, wherein the conjugate of Formula IV is present as a monodispersed mixture.
322. The use according to Claim 316, wherein the conjugate of Formula IV is amphiphilically balanced.
323. The use according to Claim 316, wherein the effective amount of the conjugate of Formula IV is present in a pharmaceutical composition.
324. The use according to Claim 316, wherein m is between 3 and 16.
325. The use according to Claim 316, wherein m is between 4 and 14.
326. The use according to Claim 316, wherein m is between 5 and 10.
327. The use according to Claim 316, wherein n is between 3 and 18.
328. The use according to Claim 316, wherein n is between 4 and 14.
329. The use according to Claim 316, wherein n is between 5 and 10.
330. The use according to Claim 316, wherein R is lower alkyl.
331. The use according to Claim 316, wherein R is C1 to C3 alkyl.
332. The use according to Claim 316, wherein R is methyl.
333. The use of an insulin polypeptide-oligomer conjugate comprising the structure of Formula V:
for the preparation of an orally administrable medicament for the treatment of diabetes mellitus.
for the preparation of an orally administrable medicament for the treatment of diabetes mellitus.
334. The use according to Claim 333, wherein the insulin polypeptide is insulin.
335. The use according to Claim 334, wherein the oligomer is coupled to the lysine at the B29 position of the insulin.
336. The use according to Claim 333, wherein the insulin polypeptide is an insulin analog selected from the group consisting of Gly A21 insulin, human; Gly A21 Gln B3 insulin, human; Ala A21 insulin, human; Ala A21 Gln B3 insulin, human; Gln B3 insulin, human; Gln B30 insulin, human; Gly A21 Glu B30 insulin, human; Gly A21 Gln B3 Glu B30 insulin, human; Gln B3 Glu B30 insulin, human; Asp B28 insulin, human; Lys B28 insulin, human; Leu B28 insulin, human;
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
Val B28 insulin, human; Ala B28 insulin, human; Asp B28 Pro B29 insulin, human; Lys B28 Pro B29 insulin, human; Leu B28 Pro B29 insulin, human; Val B28 Pro B29 insulin, human; Ala B28 Pro B29 insulin, human.
337. The use according to Claim 333, wherein the conjugate of Formula V is present as a substantially monodispersed mixture.
338. The use according to Claim 333, wherein the conjugate of Formula V is present as a monodispersed mixture.
339. The use according to Claim 333, wherein the effective amount of the conjugate of Formula V is present in a pharmaceutical composition.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26919801P | 2001-02-15 | 2001-02-15 | |
| US60/269,198 | 2001-02-15 | ||
| US34771302P | 2002-01-11 | 2002-01-11 | |
| US60/347,713 | 2002-01-11 | ||
| PCT/US2002/004440 WO2002065985A2 (en) | 2001-02-15 | 2002-02-14 | Methods of treating diabetes mellitus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2437940A1 true CA2437940A1 (en) | 2002-08-29 |
| CA2437940C CA2437940C (en) | 2012-07-10 |
Family
ID=26953561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2437940A Expired - Lifetime CA2437940C (en) | 2001-02-15 | 2002-02-14 | Methods of treating diabetes mellitus |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US7060675B2 (en) |
| EP (1) | EP1409006B1 (en) |
| JP (1) | JP4113778B2 (en) |
| KR (1) | KR100896945B1 (en) |
| AT (1) | ATE503490T1 (en) |
| AU (1) | AU2002244020B2 (en) |
| BR (1) | BRPI0207700B8 (en) |
| CA (1) | CA2437940C (en) |
| CY (1) | CY1112034T1 (en) |
| DE (1) | DE60239612D1 (en) |
| DK (1) | DK1409006T3 (en) |
| MX (1) | MXPA03007374A (en) |
| NO (1) | NO327586B1 (en) |
| NZ (1) | NZ527392A (en) |
| PT (1) | PT1409006E (en) |
| WO (1) | WO2002065985A2 (en) |
| ZA (1) | ZA200306332B (en) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6191105B1 (en) * | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
| US6867183B2 (en) * | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| US6828305B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US7713932B2 (en) * | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
| US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
| EP1270012A1 (en) * | 2001-06-21 | 2003-01-02 | Pfizer Products Inc. | Use of pulmonary administration of insulin for treatment of diabetes |
| US7196059B2 (en) * | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| US6770625B2 (en) * | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| US7030082B2 (en) * | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
| US20030198666A1 (en) * | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US7601688B2 (en) * | 2002-06-13 | 2009-10-13 | Biocon Limited | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus |
| US20040091544A1 (en) * | 2002-11-08 | 2004-05-13 | Ruff Michael D. | Coated dibasic calcium phosphate |
| ATE459370T1 (en) * | 2002-11-26 | 2010-03-15 | Biocon Ltd | MODIFIED NATRIURETIC COMPOUNDS, CONJUGATES AND USES THEREOF |
| AU2004204727B8 (en) * | 2003-01-06 | 2006-11-09 | Emisphere Technologies, Inc. | Night-time oral insulin therapy |
| JP2006519881A (en) * | 2003-03-06 | 2006-08-31 | エミスフィアー テクノロジーズ インコーポレイテッド | Oral insulin treatment and protocol |
| EP1605895A4 (en) * | 2003-03-06 | 2011-08-24 | Emisphere Tech Inc | ORAL INSULIN THERAPY AND PROTOCOL |
| PL1648933T3 (en) * | 2003-07-25 | 2010-01-29 | Conjuchem Biotechnologies Inc | Long lasting insulin derivatives and methods thereof |
| PT1660047E (en) * | 2003-08-13 | 2014-02-27 | Biocon Ltd | Micro-particle fatty acid salt solid dosage formulations for therapeutic agents |
| US20050203001A1 (en) * | 2004-03-05 | 2005-09-15 | Emisphere Technologies, Inc. | Oral insulin therapies and protocol |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| CN103223160B (en) | 2004-07-19 | 2015-02-18 | 比奥孔有限公司 | Cation complexes of insulin compund conjugates, formulation and uses thereof |
| JP2007063225A (en) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | Imidazopyridine compound |
| US8034822B2 (en) | 2006-03-08 | 2011-10-11 | Takeda San Diego, Inc. | Glucokinase activators |
| JP5386350B2 (en) | 2006-05-31 | 2014-01-15 | タケダ カリフォルニア インコーポレイテッド | Indazole and isoindole derivatives as glucokinase activators |
| MX2009000434A (en) * | 2006-07-11 | 2009-01-29 | Qps Llc | Pharmaceutical compositions for sustained release delivery of peptides. |
| WO2008049711A1 (en) | 2006-10-27 | 2008-05-02 | Novo Nordisk A/S | Peptide extended insulins |
| US8163779B2 (en) | 2006-12-20 | 2012-04-24 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2008116107A2 (en) | 2007-03-21 | 2008-09-25 | Takeda San Diego, Inc. | Piperazine derivatives as glucokinase activators |
| EP2514406A1 (en) * | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| CA2716159A1 (en) * | 2007-06-01 | 2008-12-04 | Novo Nordisk A/S | Stable non-aqueous pharmaceutical compositions |
| DK2162189T3 (en) * | 2007-06-13 | 2012-04-02 | Univ Wake Forest Health Sciences | Procedure for healing erectile function |
| PT2203181T (en) | 2007-10-16 | 2018-05-10 | Biocon Ltd | An orally administerable solid pharmaceutical composition and a process thereof |
| FR2925333B1 (en) * | 2007-12-19 | 2012-04-13 | Farid Bennis | PHARMACEUTICAL COMPOSITIONS COMPRISING AT LEAST ONE PROTEIN ACTIVE INGREDIENT PROTECTS DIGESTIVE ENZYMES |
| CN101970476B (en) * | 2008-01-09 | 2014-08-27 | 塞诺菲-安万特德国有限公司 | Novel insulin derivatives having an extremely delayed time-action profile |
| KR20100111682A (en) | 2008-01-09 | 2010-10-15 | 사노피-아벤티스 도이칠란트 게엠베하 | Novel insulin derivatives having an extremely delayed time-action profile |
| MX2010009850A (en) | 2008-03-18 | 2010-09-30 | Novo Nordisk As | Protease stabilized, acylated insulin analogues. |
| TWI451876B (en) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | Pegylated insulin lispro compounds |
| US9040723B2 (en) * | 2008-07-14 | 2015-05-26 | Biocon Limited | Method of synthesizing a substantially monodispersed mixture of oligomers |
| MX2011003117A (en) * | 2008-09-19 | 2011-04-21 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides. |
| WO2010033220A2 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Modified therapeutics peptides, methods of their preparation and use |
| HUE048608T2 (en) | 2008-10-17 | 2020-08-28 | Sanofi Aventis Deutschland | Combination of an insulin and a glp-1 agonist |
| CN102227213A (en) * | 2008-11-28 | 2011-10-26 | 诺沃—诺迪斯克有限公司 | Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides |
| AU2010208305A1 (en) | 2009-01-28 | 2011-09-08 | Smartcells, Inc. | Synthetic conjugates and uses thereof |
| CA2750223A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Exogenously triggered controlled release materials and uses thereof |
| JP5508438B2 (en) | 2009-01-28 | 2014-05-28 | スマートセルズ・インコーポレイテツド | Complex-based system for controlled drug delivery |
| BRPI1007466A2 (en) | 2009-01-28 | 2018-06-12 | Smartcells Inc | crystalline insulin conjugate, extended release formulation, and pump delivery system |
| AU2010226243A1 (en) | 2009-03-20 | 2011-09-22 | Smartcells, Inc. | Terminally-functionalized conjugates and uses thereof |
| WO2010107520A1 (en) | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
| US20110058558A1 (en) * | 2009-09-08 | 2011-03-10 | Electronics And Telecommunications Research Institute | Network control device and network control method |
| LT2498801T (en) | 2009-11-13 | 2018-05-10 | Sanofi-Aventis Deutschland Gmbh | PHARMACEUTICAL COMPOSITION COMPRISING desPro36Exendin-4(1-39)-Lys6-NH2 AND METHIONINE |
| RU2537239C2 (en) | 2009-11-13 | 2014-12-27 | Санофи-Авентис Дойчланд Гмбх | Pharmaceutical composition containing agonist glp-1, insulin and methionine |
| CN102770152B (en) | 2009-11-25 | 2016-07-06 | 阿瑞斯根股份有限公司 | The mucosal delivery of peptides |
| CA2805739A1 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
| CA2806399A1 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
| US9068013B2 (en) | 2010-07-28 | 2015-06-30 | Smart Cells, Inc. | Recombinant lectins, binding-site modified lectins and uses thereof |
| HUE031181T2 (en) | 2010-08-30 | 2017-06-28 | Sanofi Aventis Deutschland | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| RU2650616C2 (en) | 2011-08-29 | 2018-04-16 | Санофи-Авентис Дойчланд Гмбх | Pharmaceutical combination for use in glycemic control in patients with type 2 diabetes mellitus |
| AR087744A1 (en) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE |
| WO2013086927A1 (en) * | 2011-12-15 | 2013-06-20 | 上海恒瑞医药有限公司 | Human insulin analogue and acylated derivative thereof |
| EP2836508B1 (en) | 2012-04-11 | 2016-06-29 | Novo Nordisk A/S | Insulin formulations |
| MX366852B (en) | 2013-10-04 | 2019-07-25 | Merck Sharp & Dohme | Glucose-responsive insulin conjugates. |
| FI3229828T3 (en) | 2014-12-12 | 2023-05-29 | Sanofi Aventis Deutschland | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (en) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment type 2 diabetes mellitus patients |
| TW201705975A (en) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | Treatment of type 2 diabetes mellitus patients |
| AU2017378102B2 (en) | 2016-12-16 | 2022-10-13 | Novo Nordisk A/S | Insulin containing pharmaceutical compositions |
Family Cites Families (191)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US556742A (en) * | 1896-03-24 | Trace-fastener | ||
| US3256153A (en) | 1963-02-08 | 1966-06-14 | Smith Kline French Lab | Method of stabilizing wax-fat coating materials and product thereof |
| US4003792A (en) | 1967-07-01 | 1977-01-18 | Miles Laboratories, Inc. | Conjugates of acid polysaccharides and complex organic substances |
| US3950517A (en) | 1970-05-08 | 1976-04-13 | National Research Development Corporation | Insulin derivatives |
| GB1381274A (en) | 1971-01-28 | 1975-01-22 | Nat Res Dev | Insulin derivatives |
| US3919411A (en) | 1972-01-31 | 1975-11-11 | Bayvet Corp | Injectable adjuvant and compositions including such adjuvant |
| US4044196A (en) | 1972-03-30 | 1977-08-23 | Bayer Aktiengesellschaft | Crosslinked copolymers of α,β-olefinically unsaturated dicarboxylic anhydrides |
| US3852353A (en) | 1972-12-12 | 1974-12-03 | C Heaphy | Oral hypoglycemic aminophenylsulfonyl-hydrocarbylbiguanides |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| FR2408387A2 (en) | 1975-06-30 | 1979-06-08 | Oreal | COMPOSITIONS BASED ON AQUEOUS DISPERSIONS OF LIPID SPHERULES |
| US4087390A (en) | 1977-02-02 | 1978-05-02 | Eli Lilly And Company | Somatostatin analogs and intermediates thereto |
| US4093574A (en) | 1977-02-02 | 1978-06-06 | Eli Lilly And Company | Somatostatin analogs and intermediates thereto |
| GB1492997A (en) | 1976-07-21 | 1977-11-23 | Nat Res Dev | Insulin derivatives |
| JPS53116315A (en) | 1977-03-17 | 1978-10-11 | Ueno Seiyaku Oyo Kenkyujo Kk | Powder or granular containing improved sorbinic acid |
| US4100117A (en) | 1977-04-21 | 1978-07-11 | Eli Lilly And Company | Somatostatin analogs and intermediates thereto |
| US4253998A (en) | 1979-03-09 | 1981-03-03 | American Home Products Corporation | Peptides related to somatostatin |
| JPS54148722A (en) | 1978-05-12 | 1979-11-21 | Takeda Chem Ind Ltd | Nonapeptide and its preparation |
| US4277394A (en) | 1979-04-23 | 1981-07-07 | Takeda Chemical Industries, Ltd | Tetrapeptidehydrazide derivatives |
| GB2051574B (en) | 1979-05-10 | 1984-01-18 | Kyoto Pharma Ind | Adjuvant for promoting absorption of pharmacologically active substances through the rectum |
| US4348387A (en) | 1979-07-31 | 1982-09-07 | The Rockefeller University | Method and system for the controlled release of biologically active substances to a body fluid |
| US4469681A (en) | 1979-07-31 | 1984-09-04 | The Rockefeller University | Method and system for the controlled release of biologically active substances to a body fluid |
| FR2465486A1 (en) | 1979-09-21 | 1981-03-27 | Roussel Uclaf | NEW APPLICATION USING LH-RH OR AGONISTS |
| JPS5692846A (en) | 1979-12-27 | 1981-07-27 | Takeda Chem Ind Ltd | Tetrapeptide derivative and its preparation |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| IT1144743B (en) | 1981-07-09 | 1986-10-29 | Mario Cane | PERFECTED INSULIN INFUSER APPARATUS |
| US4582820A (en) | 1982-12-23 | 1986-04-15 | Research Corporation | Orally administered biologically active peptides and proteins |
| EP0092918B1 (en) | 1982-04-22 | 1988-10-19 | Imperial Chemical Industries Plc | Continuous release formulations |
| US4698264A (en) | 1982-08-02 | 1987-10-06 | Durkee Industrial Foods, Corp. | Particulate composition and process for making same |
| IL68769A (en) | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
| US4602043A (en) | 1983-07-18 | 1986-07-22 | Technology Unlimited Inc. | Treatment for hypoglycemia |
| US4585754A (en) | 1984-01-09 | 1986-04-29 | Valcor Scientific, Ltd. | Stabilization of proteins and peptides by chemical binding with chondroitin |
| US4717566A (en) | 1984-03-19 | 1988-01-05 | Alza Corporation | Dosage system and method of using same |
| US4684524A (en) | 1984-03-19 | 1987-08-04 | Alza Corporation | Rate controlled dispenser for administering beneficial agent |
| US4704394A (en) | 1984-04-25 | 1987-11-03 | Technology Unlimited, Inc. | Treatment for hyperactivity |
| US4849405A (en) | 1984-05-09 | 1989-07-18 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
| US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
| US4761287A (en) | 1984-05-03 | 1988-08-02 | Technology Unlimited, Inc. | Diabetes control by serotonin |
| US4863896A (en) | 1984-05-03 | 1989-09-05 | Technology Unlimited, Inc. | Diabetic control by combined insulin forms |
| US4963526A (en) | 1984-05-09 | 1990-10-16 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
| US4839341A (en) | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
| US4622392A (en) | 1984-06-21 | 1986-11-11 | Health Research Inc. (Roswell Park Division) | Thiophospholipid conjugates of antitumor agents |
| US4629621A (en) | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
| US4797288A (en) | 1984-10-05 | 1989-01-10 | Warner-Lambert Company | Novel drug delivery system |
| US5008241A (en) * | 1985-03-12 | 1991-04-16 | Novo Nordisk A/S | Novel insulin peptides |
| US4946828A (en) | 1985-03-12 | 1990-08-07 | Novo Nordisk A/S | Novel insulin peptides |
| US5157021A (en) | 1985-03-15 | 1992-10-20 | Novo Nordisk A/S | Insulin derivatives and pharmaceutical preparations containing these derivatives |
| US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
| US4898733A (en) * | 1985-11-04 | 1990-02-06 | International Minerals & Chemical Corp. | Layered, compression molded device for the sustained release of a beneficial agent |
| SE457326B (en) | 1986-02-14 | 1988-12-19 | Lejus Medical Ab | PROCEDURES FOR PREPARING A QUICK SUBSTANTIAL CANDLES CONTAINING BLA MICROCRISTALLIN CELLULOSA |
| US4849227A (en) | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
| ZA877505B (en) | 1986-10-14 | 1989-05-30 | Lilly Co Eli | Process for transforming a human insulin precursor to human insulin |
| GB8706313D0 (en) | 1987-03-17 | 1987-04-23 | Health Lab Service Board | Treatment & prevention of viral infections |
| US5093198A (en) | 1987-06-19 | 1992-03-03 | Temple University | Adjuvant-enhanced sustained release composition and method for making |
| US4822337A (en) | 1987-06-22 | 1989-04-18 | Stanley Newhouse | Insulin delivery method and apparatus |
| DE3721721C1 (en) | 1987-07-01 | 1988-06-09 | Hoechst Ag | Process for coating granules |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US4840341A (en) * | 1988-05-09 | 1989-06-20 | Hasegawa Gary K | Clip and holder |
| DK257988D0 (en) * | 1988-05-11 | 1988-05-11 | Novo Industri As | NEW PEPTIDES |
| JPH01308231A (en) | 1988-06-03 | 1989-12-12 | Takeda Chem Ind Ltd | Stabilized pharmaceutical composition and production thereof |
| US5055300A (en) | 1988-06-17 | 1991-10-08 | Basic Bio Systems, Inc. | Time release protein |
| DK336188D0 (en) | 1988-06-20 | 1988-06-20 | Nordisk Gentofte | propeptides |
| JPH0720857B2 (en) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | Liposome and its manufacturing method |
| US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
| US5306500A (en) | 1988-11-21 | 1994-04-26 | Collagen Corporation | Method of augmenting tissue with collagen-polymer conjugates |
| US5716927A (en) * | 1988-12-23 | 1998-02-10 | Novo Nordisk A/S | Insulin analogs having a modified B-chain |
| FI913037A7 (en) | 1988-12-23 | 1991-06-20 | Novo Nordisk As | Human insulin analogues |
| US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| IT1229514B (en) | 1989-01-30 | 1991-09-03 | Farmhispania S A A Montme | SYNTHETIC AMPHIPHILIC GLYCOCONUGATES FOR NEUROLOGICAL USE. |
| US5514646A (en) * | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| US5182258A (en) | 1989-03-20 | 1993-01-26 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5108568A (en) | 1989-07-07 | 1992-04-28 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Controlled method of reducing electrophoretic mobility of macromolecules, particles or cells |
| US5286637A (en) | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5650388A (en) | 1989-11-22 | 1997-07-22 | Enzon, Inc. | Fractionated polyalkylene oxide-conjugated hemoglobin solutions |
| US5312808A (en) | 1989-11-22 | 1994-05-17 | Enzon, Inc. | Fractionation of polyalkylene oxide-conjugated hemoglobin solutions |
| CA2030174C (en) | 1990-01-10 | 1996-12-24 | Anthony H. Cincotta | Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| US5126324A (en) | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| DD297249A5 (en) | 1990-08-07 | 1992-01-02 | Veb Mineralwollewerk Flechtingen Bereich F/E Mineralwolle,De | METHOD FOR AUTOMATIC MONITORING OF THE BONED GRADE ON MATERIAL RAILS |
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Pharmaceutical oral, enteral or by-inhalation dosage form for suppressing an autoimmune response associated with type i diabetes |
| US5468727A (en) | 1990-12-13 | 1995-11-21 | Board Of Regents, The University Of Texas System | Methods of normalizing metabolic parameters in diabetics |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5321009A (en) | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
| DE69229779T2 (en) | 1991-04-19 | 1999-12-23 | Lds Technologies, Inc. | CONVERTIBLE MICROEMULSION CONNECTIONS |
| FR2675807B1 (en) | 1991-04-23 | 1994-07-01 | Medgenix Group Sa | CONJUGATE OF CALCITONIN AND POLYETHYLENE GLYCOL. |
| US5304473A (en) | 1991-06-11 | 1994-04-19 | Eli Lilly And Company | A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production |
| US5205415A (en) * | 1991-07-10 | 1993-04-27 | The Standard Commercial Tobacco Co., Inc. | Modular classifier |
| CH683149A5 (en) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Process for the preparation of microspheres of a biodegradable polymeric material. |
| AU667316B2 (en) | 1991-07-26 | 1996-03-21 | Smithkline Beecham Corporation | W/O microemulsions |
| US5206219A (en) | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
| US5693769A (en) | 1991-12-13 | 1997-12-02 | Transcell Technologies, Inc. | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
| US5320094A (en) | 1992-01-10 | 1994-06-14 | The Johns Hopkins University | Method of administering insulin |
| ATE142484T1 (en) | 1992-01-17 | 1996-09-15 | Alfatec Pharma Gmbh | SOLID BODY CONTAINING ACTIVE INGREDIENTS WITH A FRAMEWORK OF HYDROPHILIC MACROMOLECLES AND METHOD FOR THE PRODUCTION THEREOF |
| GB9212511D0 (en) | 1992-06-12 | 1992-07-22 | Cortecs Ltd | Pharmaceutical compositions |
| US5262172A (en) | 1992-06-19 | 1993-11-16 | Digestive Care Inc. | Compositions of gastric acid-resistant microspheres containing buffered bile acids |
| US5415872A (en) | 1992-06-22 | 1995-05-16 | Digestive Care Inc. | Compositions of gastric acid-resistant microspheres containing salts of bile acids |
| US5420108A (en) | 1992-09-14 | 1995-05-30 | Shohet; Isaac H. | Method of controlling diabetes mellitus |
| US6093391A (en) | 1992-10-08 | 2000-07-25 | Supratek Pharma, Inc. | Peptide copolymer compositions |
| GB9316895D0 (en) | 1993-08-13 | 1993-09-29 | Guy S And St Thomas Hospitals | Hepatoselective insulin analogues |
| US5298643A (en) | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
| US5349001A (en) | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
| US5364838A (en) | 1993-01-29 | 1994-11-15 | Miris Medical Corporation | Method of administration of insulin |
| US5321095A (en) | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
| US5298410A (en) | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| TW402506B (en) | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
| IS1796B (en) | 1993-06-24 | 2001-12-31 | Ab Astra | Inhaled polypeptide formulation composition which also contains an enhancer compound |
| US5830853A (en) | 1994-06-23 | 1998-11-03 | Astra Aktiebolag | Systemic administration of a therapeutic preparation |
| US5506203C1 (en) | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
| US5747445A (en) | 1993-06-24 | 1998-05-05 | Astra Aktiebolag | Therapeutic preparation for inhalation |
| US6342225B1 (en) | 1993-08-13 | 2002-01-29 | Deutshces Wollforschungsinstitut | Pharmaceutical active conjugates |
| CZ287945B6 (en) | 1993-09-17 | 2001-03-14 | Novo Nordisk A/S | Insulin derivative and pharmaceutical preparation in which it is comprised and which is intended for treating diabetes mellitus |
| HU218923B (en) | 1993-10-06 | 2000-12-28 | Nicox S.A. | Nitric esters having anti-inflammatory and/or analgesic activity, pharmaceutical compns. contg. them and process for their preparation |
| US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| DE69434626D1 (en) | 1993-11-17 | 2006-04-20 | Athena Neurosciences Inc | TRANSPARENT LIQUID FOR THE ADMINISTRATION OF CAPTIVATED MEDICAMENTS |
| CA2183577C (en) | 1994-03-07 | 2007-10-30 | John S. Patton | Methods and compositions for pulmonary delivery of insulin |
| GB9406094D0 (en) | 1994-03-28 | 1994-05-18 | Univ Nottingham And University | Polymer microspheres and a method of production thereof |
| RU2145595C1 (en) | 1994-05-10 | 2000-02-20 | Никокс С.А. | Nitroxycompounds and pharmaceutical composition based on thereof showing anti-inflammatory, analgetic and antithrombocytic activity |
| WO1995032219A1 (en) | 1994-05-20 | 1995-11-30 | Hisamitsu Pharmaceutical Co., Inc. | Protein or polypeptide, process for producing the same, and intermediate compound tehrefor |
| US5504188A (en) | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
| US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
| US6165976A (en) | 1994-06-23 | 2000-12-26 | Astra Aktiebolag | Therapeutic preparation for inhalation |
| US5730990A (en) | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| GB9417524D0 (en) | 1994-08-31 | 1994-10-19 | Cortecs Ltd | Pharmaceutical compositions |
| CA2199005A1 (en) | 1994-09-01 | 1996-03-07 | Emile Bourland (Deceased) | Compositions and methods for delivery of polypeptides |
| US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
| US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| US5646242A (en) | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
| AU697440B2 (en) | 1994-12-07 | 1998-10-08 | Novozymes A/S | Polypeptide with reduced allergenicity |
| GB9424902D0 (en) | 1994-12-09 | 1995-02-08 | Cortecs Ltd | Solubilisation Aids |
| SE9404468D0 (en) | 1994-12-22 | 1994-12-22 | Astra Ab | Powder formulations |
| US5843866A (en) | 1994-12-30 | 1998-12-01 | Hampshire Chemical Corp. | Pesticidal compositions comprising solutions of polyurea and/or polyurethane |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5907030A (en) | 1995-01-25 | 1999-05-25 | University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
| KR0150565B1 (en) | 1995-02-15 | 1998-08-17 | 김정재 | A process for preparing human proinsulin by recombinant dna technology |
| US6251856B1 (en) | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
| YU18596A (en) | 1995-03-31 | 1998-07-10 | Eli Lilly And Company | Analogous formulations of monomer insulin |
| US5606038A (en) | 1995-04-10 | 1997-02-25 | Competitive Technologies, Inc. | Amphiphilic polyene macrolide antibiotic compounds |
| DE741187T1 (en) | 1995-05-05 | 1997-04-30 | Hoffmann La Roche | Recombinant Obesity (OB) Proteins |
| US5653987A (en) * | 1995-05-16 | 1997-08-05 | Modi; Pankaj | Liquid formulations for proteinic pharmaceuticals |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| US5704910A (en) | 1995-06-05 | 1998-01-06 | Nephros Therapeutics, Inc. | Implantable device and use therefor |
| US5700904A (en) | 1995-06-07 | 1997-12-23 | Eli Lilly And Company | Preparation of an acylated protein powder |
| US5631347A (en) | 1995-06-07 | 1997-05-20 | Eli Lilly And Company | Reducing gelation of a fatty acid-acylated protein |
| US5714519A (en) | 1995-06-07 | 1998-02-03 | Ergo Science Incorporated | Method for regulating glucose metabolism |
| GB9516268D0 (en) | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
| CA2658039A1 (en) | 1995-09-21 | 1997-03-27 | Genentech, Inc. | Human growth hormone variants |
| US5766620A (en) | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| US5948751A (en) | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
| GB9613858D0 (en) | 1996-07-02 | 1996-09-04 | Cortecs Ltd | Hydrophobic preparations |
| US5905140A (en) | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
| US6180604B1 (en) | 1996-08-21 | 2001-01-30 | Micrologix Biotech Inc. | Compositions and methods for treating infections using analogues of indolicidin |
| US5874111A (en) | 1997-01-07 | 1999-02-23 | Maitra; Amarnath | Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles |
| US5830918A (en) | 1997-01-15 | 1998-11-03 | Terrapin Technologies, Inc. | Nonpeptide insulin receptor agonists |
| ME00578A (en) | 1997-02-05 | 2011-12-20 | Use of gastrointestinal lipase inhibitors | |
| US6043214A (en) | 1997-03-20 | 2000-03-28 | Novo Nordisk A/S | Method for producing powder formulation comprising an insulin |
| US5898028A (en) | 1997-03-20 | 1999-04-27 | Novo Nordisk A/S | Method for producing powder formulation comprising an insulin |
| US6310038B1 (en) | 1997-03-20 | 2001-10-30 | Novo Nordisk A/S | Pulmonary insulin crystals |
| CO4750643A1 (en) | 1997-06-13 | 1999-03-31 | Lilly Co Eli | STABLE FORMULATION OF INSULIN CONTAINING L-ARGININ AND PROTAMINE |
| EP1039920A4 (en) | 1997-10-24 | 2003-05-28 | Lilly Co Eli | Fatty acid-acylated insulin analogs |
| ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
| JP2002518408A (en) | 1998-06-12 | 2002-06-25 | キングス・カレツジ・ロンドン | Insulin analogues |
| US6211144B1 (en) | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
| DK1146896T3 (en) | 1999-01-26 | 2002-09-02 | Lilly Co Eli | Formulations containing monodisperse hexameric acylated insulin analogues |
| DE19908041A1 (en) | 1999-02-24 | 2000-08-31 | Hoecker Hartwig | Covalently bridged insulin dimers |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| KR100345214B1 (en) | 1999-08-17 | 2002-07-25 | 이강춘 | The nasal transmucosal delivery of peptides conjugated with biocompatible polymers |
| US6323311B1 (en) | 1999-09-22 | 2001-11-27 | University Of Utah Research Foundation | Synthesis of insulin derivatives |
| US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| US6867183B2 (en) | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6900033B2 (en) | 2001-06-04 | 2005-05-31 | Human Genome Sciences, Inc. | Methods and compositions for modulating ACE-2 activity |
| US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
| US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6828305B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| ES2333781T3 (en) | 2001-09-07 | 2010-03-01 | Biocon Limited | SYNTHESIS PROCEDURES OF INSULIN-OLIGOMERO POLYPEPTIDE CONJUGATES AND PROINSULIN-OLIGOMERO POLYPEPTIDE CONJUGATES, AND SYNTHESIS PROCEDURES OF THE SAME. |
| US6913903B2 (en) * | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| CN103223160B (en) * | 2004-07-19 | 2015-02-18 | 比奥孔有限公司 | Cation complexes of insulin compund conjugates, formulation and uses thereof |
-
2002
- 2002-02-13 US US10/075,097 patent/US7060675B2/en not_active Expired - Lifetime
- 2002-02-14 KR KR1020037010645A patent/KR100896945B1/en not_active Expired - Lifetime
- 2002-02-14 DK DK02709541.3T patent/DK1409006T3/en active
- 2002-02-14 MX MXPA03007374A patent/MXPA03007374A/en active IP Right Grant
- 2002-02-14 AT AT02709541T patent/ATE503490T1/en active
- 2002-02-14 CA CA2437940A patent/CA2437940C/en not_active Expired - Lifetime
- 2002-02-14 AU AU2002244020A patent/AU2002244020B2/en not_active Expired
- 2002-02-14 EP EP02709541A patent/EP1409006B1/en not_active Expired - Lifetime
- 2002-02-14 BR BRPI0207700A patent/BRPI0207700B8/en not_active IP Right Cessation
- 2002-02-14 WO PCT/US2002/004440 patent/WO2002065985A2/en not_active Ceased
- 2002-02-14 DE DE60239612T patent/DE60239612D1/en not_active Expired - Lifetime
- 2002-02-14 JP JP2002565546A patent/JP4113778B2/en not_active Expired - Lifetime
- 2002-02-14 NZ NZ527392A patent/NZ527392A/en not_active IP Right Cessation
- 2002-02-14 PT PT02709541T patent/PT1409006E/en unknown
-
2003
- 2003-08-14 ZA ZA2003/06332A patent/ZA200306332B/en unknown
- 2003-08-14 NO NO20033617A patent/NO327586B1/en not_active IP Right Cessation
-
2005
- 2005-12-21 US US11/314,309 patent/US7423014B2/en not_active Expired - Fee Related
-
2006
- 2006-06-15 US US11/424,295 patent/US7381702B2/en not_active Expired - Fee Related
-
2011
- 2011-06-27 CY CY20111100609T patent/CY1112034T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7423014B2 (en) | 2008-09-09 |
| US20030050228A1 (en) | 2003-03-13 |
| DE60239612D1 (en) | 2011-05-12 |
| ZA200306332B (en) | 2005-07-27 |
| US7060675B2 (en) | 2006-06-13 |
| CY1112034T1 (en) | 2015-11-04 |
| KR100896945B1 (en) | 2009-05-14 |
| EP1409006B1 (en) | 2011-03-30 |
| JP4113778B2 (en) | 2008-07-09 |
| NO327586B1 (en) | 2009-08-24 |
| WO2002065985A2 (en) | 2002-08-29 |
| ATE503490T1 (en) | 2011-04-15 |
| US7381702B2 (en) | 2008-06-03 |
| NZ527392A (en) | 2008-01-31 |
| BRPI0207700B8 (en) | 2021-05-25 |
| DK1409006T3 (en) | 2011-06-14 |
| BR0207700A (en) | 2005-07-19 |
| NO20033617L (en) | 2003-10-15 |
| US20060100137A1 (en) | 2006-05-11 |
| EP1409006A4 (en) | 2005-01-19 |
| MXPA03007374A (en) | 2003-12-04 |
| NO20033617D0 (en) | 2003-08-14 |
| AU2002244020B2 (en) | 2007-08-16 |
| EP1409006A2 (en) | 2004-04-21 |
| KR20040043113A (en) | 2004-05-22 |
| CA2437940C (en) | 2012-07-10 |
| PT1409006E (en) | 2011-07-01 |
| BRPI0207700B1 (en) | 2016-06-07 |
| JP2004527487A (en) | 2004-09-09 |
| WO2002065985A3 (en) | 2004-02-19 |
| US20060293219A1 (en) | 2006-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2437940A1 (en) | Methods of treating diabetes mellitus | |
| RU2311922C2 (en) | Zinc-free and zinc-depleted insulin compositions of increased stability | |
| CA2471769C (en) | Oral insulin therapy | |
| Farraj et al. | Nasal administration of insulin using bioadhesive microspheres as a delivery system | |
| AU2002244020A1 (en) | Methods of treating diabetes mellitus | |
| AU2009203530B2 (en) | Methods and compositions for oral administration of insulin | |
| JP2004527487A5 (en) | ||
| JP2002526379A (en) | Compositions for enhancing insulin activity and methods thereof | |
| ZA200406332B (en) | ACC inhibitors. | |
| CN114901683A (en) | Insulin derivatives | |
| EP4361174A1 (en) | Acylated insulin-containing pharmaceutical composition | |
| US7601688B2 (en) | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus | |
| CN115947822A (en) | Long-acting acylated insulin derivative and pharmaceutical composition and application thereof | |
| WO2024164567A1 (en) | Oral glp-1 analogue solid lipid nanoparticle, and preparation method therefor and use thereof | |
| JP3263598B2 (en) | Bioactive peptide composition for nasal absorption | |
| AU2427092A (en) | Leukotriene receptor antagonist-antihistamine complex | |
| WO2023143458A1 (en) | Acylated insulin | |
| EP1790351A1 (en) | Permucosal composition and method of improving permucosal absorption | |
| HK40103864A (en) | Acylated insulin-containing pharmaceutical composition | |
| Kesavadev et al. | Newer insulins on the horizon | |
| CN112915078A (en) | Application of lactucin in preparation of medicine for treating metabolic syndrome | |
| Sharma et al. | Insulin drug delivery: novel approaches | |
| Kalra et al. | Recent patents on oral insulin | |
| CA2560798A1 (en) | Administering pharmaceutical compositions to the mammalian central nervous system | |
| JPH04305529A (en) | Pharmaceutical for pernasal administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20220214 |